April 08, 2020
A California federal judge on Wednesday entered final judgment awarding Juno Therapeutics and Sloan Kettering enhanced damages of over $389 million while boosting the total award to over $1.1 billion after a jury found that Kite Pharma willfully infringed a patent for a cancer immunotherapy.
January 22, 2020
A Bristol-Myers Squibb subsidiary and Memorial Sloan Kettering Cancer Center have asked a California federal judge to more than double a jury's $752 million patent infringement verdict against a Gilead unit for its cancer treatment Yescarta, saying the company must be punished for its "undisputed willfulness."
December 13, 2019
A California federal jury awarded Juno Therapeutics and Sloan Kettering $752 million on Friday after finding that Kite Pharma willfully infringed a patent for cancer immunotherapy, bringing a dramatic end to a high-stakes trial that hinged largely on a purported typo.
December 12, 2019
Juno Therapeutics and Sloan Kettering's bid for $752 million in damages over Kite Pharma's alleged infringement of a cancer immunotherapy patent is "just crazy," Kite's attorney told a California federal jury during closing arguments Thursday, noting the drug at issue has only logged $604 million in sales.
December 11, 2019
Kite Pharma shouldn't be allowed to "exploit" a simple typo to "kill" a valuable cancer patent, a lawyer for Juno Therapeutics and Sloan Kettering told a California jury during closings Wednesday, arguing that Kite infringed the patent and owes $752 million in damages.
December 10, 2019
Contradicting testimony from Kite Pharma founder Arie Belldegrun, the company's former CEO conceded under questioning in a California federal trial Tuesday that a meeting Belldegrun had with a Sloan Kettering executive was about potentially licensing a cancer immunotherapy patent it's now accused of infringing.
December 09, 2019
An economist hired by Sloan Kettering and Juno Therapeutics told a California jury Monday that defendant Kite Pharma would have paid $752 million to license the cancer immunotherapy patent it's accused of infringing, saying that estimate is large but "conservative."
December 05, 2019
The founder of Kite Pharma on Thursday countered claims that he sought to license a Sloan Kettering-developed patent that Kite is accused of infringing, testifying to a California federal jury that he only pursued a meeting with a Sloan Kettering researcher to "get access to his patients," not his patent.
December 04, 2019
A co-inventor of a cancer immunotherapy treatment licensed by Juno Therapeutics told a California jury on Wednesday that he never imagined that answering a phone call from a "towering figure" in his field would come back to bite him and result in Kite Pharma infringing his patent.
December 03, 2019
Lawyers for Juno Therapeutics and Kite Pharma delivered opening statements Tuesday in Juno's infringement suit over its groundbreaking cancer immunotherapy — a potentially multibillion-dollar fight that may turn on whether a California federal jury believes Juno's patent contained a simple typo or not.